Bellvitge University Hospital (HUB) has been recognised as a reference centre in Spain for destination therapy using Left Ventricular Assist Devices (LVADs), marking a significant advance in the treatment of patients suffering from advanced heart failure. This prestigious designation grants HUB the opportunity to participate in an upcoming LVAD monitoring study for destination therapy. The study is being coordinated by the Galician Agency for Knowledge Management in Health (ACIS) and is scheduled to commence in the coming weeks.
While medical treatments for heart failure (HF) have seen significant advancements, a considerable number of patients still progress to advanced or end-stage disease. In cases where traditional medical interventions are no longer effective, heart transplantation is the preferred option. However, the limited availability of suitable organs and extended waiting times have prompted the emergence of Left Ventricular Assist Devices (LVADs) as a viable therapeutic alternative. For patients who may not qualify for heart transplantation due to age or comorbidities, LVADs, when used as destination therapy, represent a primary alternative.
The study in which HUB is participating aims to address significant uncertainties regarding the safety, effectiveness, economic impact, and acceptability of LVADs as destination therapy. The primary objectives of the study include:
- To determine the safety of LVAD devices in terms of adverse events associated with their use.
- To analyse the effectiveness of LVADs in terms of long-term survival, quality of life, patient satisfaction and adherence to treatment.
- To assess the economic impact associated with the use of LVADs as destination therapy, as well as organisational, social, ethical and legal aspects related to their use.
Bellvitge Hospital, renowned state-wide leader in the implantation of long-duration Left Ventricular Assist Devices (LVADs), performs approximately 8-10 LVAD implantations yearly and currently provides care to 18 patients with mechanical hearts in the Advanced Heart Failure Unit.
These advances, the result of the joint work of the Heart Surgery and Cardiology Departments at Bellvitge Hospital, represent hope for patients with terminal heart disease, for whom LVADs represent a chance of life.